Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 4/20 | 0.60 |
| ▸ | MAPK14 | Q16539 | 14/20 | 0.58 |
| ▸ | MAPK13 | O15264 | 13/20 | 0.58 |
| ▸ | MAPK12 | P53778 | 13/20 | 0.58 |
| ▸ | MAPK11 | Q15759 | 13/20 | 0.58 |
| ▸ | TGFBR2 | P37173 | 3/20 | 0.57 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.56 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.56 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.56 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.56 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.56 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.56 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.56 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4805174 | 0.82 | PTGS2 (0.63) | TGFBR1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL27311897 | 0.81 | MAPK14 (0.78) | MAPK14MAPK13MAPK12MAPK11MAP4K4 | |
| SCHEMBL20550895 | 0.79 | MAPK14 (0.71) | MAPK14MAPK13MAPK12MAPK11MAP4K4 | |
| SCHEMBL23795643 | 0.77 | MAPK14 (0.66) | TGFBR1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL18041759 | 0.77 | TGFBR1 (1.00) | TGFBR1 | |
| SCHEMBL21759155 | 0.76 | TGFBR1 (0.74) | TGFBR1TGFBR2 | |
| SCHEMBL23795646 | 0.76 | MAPK14 (0.49) | TGFBR1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL5756916 | 0.75 | TGFBR1 (0.42) | TGFBR1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL31568891 | 0.75 | PTGS2 (0.61) | TGFBR1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL18041856 | 0.75 | TGFBR1 (1.00) | TGFBR1TGFBR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250154179-A1 | GOLD (I) GEFITINIB DERIVATIVES AND PREPARATION METHOD AND APPLICATION THEREOF | TONGJI HOSPITAL, TONGJI MEDICAL COLLEGE, HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2025-05-15 | — | — | US | claimed |
| CN-117986277-A | Parafluorobenzaldehyde derivative, preparation method thereof and application thereof in pharmacy | 南京市第一医院 | 2024-05-07 | — | — | CN | claimed |
| US-20250154179-A1 | GOLD (I) GEFITINIB DERIVATIVES AND PREPARATION METHOD AND APPLICATION THEREOF | TONGJI HOSPITAL, TONGJI MEDICAL COLLEGE, HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2025-05-15 | — | — | US | disclosed |
| CN-110551156-B | Specific group-modified N1, N3-substituted 4,5-diaryl imidazole ring carbene rhodium complex and preparation method and application thereof | 南京中医药大学 | 2022-11-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154179-A1 | GOLD (I) GEFITINIB DERIVATIVES AND PREPARATION METHOD AND APPLICATION THEREOF | EGFR, MAP2K4, MAP2K3 | TGFBR1 787/4885MAPK14 347/4885MAPK13 517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.